Cochrane · systematic review · CD011612
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
Dean, RL, Hurducas, C, Hawton, K, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
12
No studies
3
Included studies
NR
No studies 3 · 20%Ungraded 0 · 0%Very low 6 · 40%Low 3 · 20%Moderate 3 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsKetamine compared to placebo for adults with unipolar major depressive disorder
Population: adults (aged 18 years+) with unipolar major depressive disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy: number of participants who respond to treatment ‐ at 24 hours (Response) Ketamine vs placebo | OR 3.94 [1.54, 10.1] | NR | Very low |
Efficacy: number of participants who achieve remission ‐ at 24 hours (Remission) Ketamine vs placebo | OR 5.6 [1.07, 29.46] | NR | Very low Downgraded: risk of bias, inconsistency |
Depression rating scale score ‐ at 24 hours Ketamine vs placebo | no estimate extracted | NR | Very low |
Acceptability: total dropouts№ of participants: 201(6 RCTs) Ketamine vs placebo | OR 1.25 [0.19, 8.28] | NR | Very low |
Acceptability: dropouts due to adverse effects ‐ not reported Ketamine vs placebo | no estimate extracted | NR | No studies |
Ketamine compared to midazolam for adults with unipolar major depressive disorder
Population: adults (aged 18 years+) with unipolar major depressive disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy: number of participants who respond to treatment ‐ at 24 hours Ketamine vs midazolam | OR 2.48 [1, 6.18] | NR | Very low Downgraded: risk of bias |
Efficacy: number of participants who achieve remission ‐ at 24 hours Ketamine vs midazolam | OR 2.21 [0.67, 7.32] | NR | Low Downgraded: risk of bias, inconsistency |
Depression rating scale score ‐ at 24 hours Ketamine vs midazolam | no estimate extracted | NR | Very low Downgraded: risk of bias |
Acceptability: total dropouts№ of participants: 72(1 RCT) Ketamine vs midazolam | OR 0.33 [0.05, 2.09] | NR | Low Downgraded: risk of bias, inconsistency |
Acceptability: dropouts due to adverse effects ‐ not reported Ketamine vs midazolam | no estimate extracted | NR | No studies |
Esketamine compared to placebo for adults with unipolar major depressive disorder
Population: adults (aged 18 years+) with unipolar major depressive disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy: number of participants who respond to treatment ‐ at 24 hours (Response) Esketamine vs placebo | OR 2.11 [1.2, 3.68] | NR | Low Downgraded: risk of bias |
Efficacy: number of participants who achieve remission ‐ at 24 hours (Remission) Esketamine vs placebo | OR 2.74 [1.71, 4.4] | NR | Moderate Downgraded: risk of bias |
Depression rating scale score ‐ at 24 hours Esketamine vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Acceptability: total dropouts№ of participants: 773(5 RCTs) Esketamine vs placebo | OR 1.58 [0.92, 2.73] | NR | Moderate Downgraded: risk of bias |
Acceptability: dropouts due to adverse effects ‐ not reported Esketamine vs placebo | no estimate extracted | NR | No studies |